Ligand制药公司近日宣布大幅上调2026年财务预期，将全年营收指引区间调整为2.7亿至3.1亿美元。其中特许权使用费收入预计将贡献2.25亿至2.5亿美元，展现出公司核心授权业务强劲的增长动能。
这一乐观预测主要得益于其合作药企多项创新药物的商业化进展超预期。通过精准的授权合作模式，Ligand持续扩大其生物技术资产组合的价值变现能力。此次指引上调也反映出市场对其合作伙伴研发管线商业化前景的积极预期。
作为专注医药特许权投资的企业，XOMA公司通过持有Ligand相关权益间接受益于这一利好消息。生物医药领域特许权经营模式的成熟发展，正为行业带来更可持续的增长路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.